viewOptiscan Imaging Ltd

Optiscan Imaging's endomicroscope being used in clinical gastroenterology study


Optiscan Imaging (ASX: OIL) has noted commencement of a clinical study that is introducing Optiscan's second generation endomicroscopy platform into the field of gastroenterology.

The study is being undertaken by gastroenterologists and scientists from the Garvan Institute of Medical research and St Vincent's Hospital in Sydney, in affiliation with the University of New South Wales.

The gastroenterology market is now well established as a result of extensive use of Optiscan's previous generation platform via a product marketed by Pentax Medical Corporation.

The study has enabled the incorporation of the latest advances in Optiscan's technology into a high definition Olympus endoscope.

The resultant system combines advanced features of the Olympus endoscope with Optiscan's latest developments in microscopic imaging during endoscopy.

The result is an endoscope with a level of performance never before trialled in humans, incorporating desirable features discovered using the first generation product during thousands of endoscopy procedures, and other advances in endoscopic imaging.

This study will apply these novel features in dynamic events relating to the permeability, or "leakiness" of the gut lining and how it is altered by inflammatory diseases.

For Optiscan, the commencement of patient recruitment in this study is a key milestone in its strategy to advance the second generation platform into commercially viable markets.

The same platform is currently the subject of product development for neurosurgery under a commercial partnership with Carl Zeiss of Germany, as well as a supply agreement recently secured with UK based MR Solutions for global supply into the pre-clinical imaging market.

Optiscan is capitalised at around $10 million.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Optiscan Imaging Ltd

Price: 0.043 AUD

Market: ASX
Market Cap: $20.54 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



ioneer Ltd's Bernard Rowe hails new boric acid distribution and sales agreements

ioneer Ltd's (ASX:INR) Bernard Rowe speaks to Proactive's Andrew Scott after securing two distribution and sales agreements for the supply of boric acid from its Rhyolite Ridge Lithium-Boron Project in Nevada, USA. The three-year boric acid distribution and sales agreements were signed with...

1 day, 13 hours ago

2 min read